Food, Global Health 2 min

Artificial sweeteners: certain adverse metabolic effects revealed in a preclinical model

PRESS RELEASE- INRA researchers, in collaboration with the University of Adelaide, Australia, studied the effects that a widely used artificial sweetener blend, i.e. acesulfame K-sucralose, has on metabolism. For the first time, they revealed – in animals – an increase in glucose absorption, particularly in the brain and fatty tissues, indicating certain undesirable effects on metabolism and insulin sensitivity. These results were published in the 24 July 2019 edition of the European Journal of Nuclear Medicine and Molecular Imaging.

Published on 25 July 2019

illustration Artificial sweeteners: certain adverse metabolic effects revealed in a preclinical model
© INRAE

The obesity pandemic has led to sugar being partially replaced by artificial sweeteners in human diets. These food additives are used for their intense sweetening power and several types are currently available on the market. The use of aspartame has waned in favour of other substances such as an acesulfame potassium (K) - sucralose blend that can be found in nearly 90% of “light” drinks. While artificial sweeteners undoubtedly lower calorie intake, not enough data exist on their metabolic effects, especially as there is reason to suspect that such substances may have adverse secondary effects, particularly a decrease in insulin sensitivity that could lead, over time, to type 2 diabetes.1

A gauche : imagerie multimodale d’une coupe de cerveau du porc représentant en nuances de gris le scanner X et en fausses couleurs la captation du glucose par le cerveau au moyen de la tomographie positronique – une méthode d’imagerie nucléaire quantitative. A droite : représentation en 3 dimensions des différences de connectivité métabolique des neurones au niveau du cerveau chez les porcs témoins et ceux ayant reçu le mélange Acesulfame K Sucralose (figure réalisée à partir d’un atlas développé au sein de

For the first time, INRA and University of Adelaide researchers tested the metabolic effects of an acesulfame K – sucralose blend on animals. Through quantitative nuclear imaging, they were able to analyse glucose uptake and insulin sensitivity in specific organs. Each organ, whether muscle, liver, intestines, brain, etc., contributes to a certain percentage of the body’s insulin sensitivity based on two parameters, i.e. how much glucose that organ absorbs and how much the organ weighs. That is why no metabolic effects may be observed in the body as a whole while far-reaching changes have taken place in individual organs.

Over a period of three months, researchers gave mini-pigs (an animal model for human nutrition and medical research) an acesulfame K - sucralose blend at the exact same daily dose as a person who has a half-litre of “light” drinks. At the end of that period, quantitative nuclear imaging did not reveal any changes in the overall body glucose uptake and insulin sensitivity. However, glucose uptake in the brain, liver, part of the digestive tract and visceral fat had nearly doubled. There were also increased metabolic connections between the front of the cortex and deeper structures in the brain, a phenomenon that has also been observed in obese individuals (patients with pre-type 2 diabetes).

To conclude, long-term ingestion of artificial sweeteners at doses equivalent to some people’s daily intake led to far-reaching adverse changes in glucose metabolism, particularly in the brain. Although no explanation can be given at this point, the phenomena seen are the same as those that occur when obese individuals gain weight.

In view of the fact that such substances do have beneficial effects in terms of calorie intake, these new results suggest that, at the very least, further studies should be carried out to evaluate the relative benefits and risks of ingesting such additives.

 

1Insulin is a hormone produced by the pancreas that regulates blood sugar levels. In conventional models, excess weight increase leads to reduced insulin sensitivity (the cells become less sensitive to the hormone – known as prediabetes) and then, depending on the individual’s susceptibility, to type 2 diabetes.

Publication

Low-calorie sweeteners augment tissue-specific insulin sensitivity in a large animal model of obesity. Charles-Henri Malbert, Michael Horowitz, Richard L. Young. European Journal of Nuclear Medicine and Molecular Imaging. 24 juillet 2019.
https://doi.org/10.1007/s00259-019-04430-4 

Press office INRAE

Scientific contact

Charles-Henri Malbertcharles-Henri.malbert@inrae.frUnité ANI-SCAN

Centre

Division

Learn more

Food, Global Health

Obésité : vers une piste préventive du diabète de type 2

COMMUNIQUE DE PRESSE - L’une des conséquences pathologiques les plus graves de l’obésité morbide reste le développement d’un diabète de type 2. Ce dernier est lui-même la conséquence d’une perte de la sensibilité à l’insuline des tissus.En couplant des solutions innovantes de chirurgie par coelioscopie, de micro-électronique et d’imagerie de pointe, les chercheurs de l’Inra, en collaboration avec la société AXONIC, ont développé chez un modèle animal une alternative à la chirurgie bariatrique, pratique lourde et irréversible, visant à rétablir la sensibilité à l’insuline. Cette stratégie thérapeutique met en œuvre la stimulation électrique du nerf vague au niveau de l’abdomen, et ouvre de prometteuses perspectives en termes de prévention du diabète de type 2.

04 March 2020

Food, Global Health

Un vaccin contre la toxoplasmose pour les singes Saïmiris

Les Saïmiris, petits singes d’Amérique du Sud, sont particulièrement sensibles à la toxoplasmose, une infection parasitaire due au protozoaire Toxoplasma gondii. Une campagne de vaccination de Saïmiris a débuté en septembre 2017 dans cinq parcs zoologiques français. Le vaccin contre T. gondii a été développé par l’équipe BioMédicaments Anti Parasitaires (BioMAP) de l'unité mixte de recherche Infectiologie et santé publique (UMR ISP, Inra-Université de Tours), en collaboration avec la société Vaxinano.

19 December 2019

Food, Global Health

L'Inra, la société Valorex et l’association Bleu-Blanc-Cœur signent une convention cadre pour consolider et développer des modèles agricoles et alimentaires durables

COMMUNIQUE DE PRESSE - Le 8 novembre 2019, Philippe Mauguin, Président directeur général de l’Inra et Pierre Weill, co-président de l’association Bleu-Blanc-Cœur et fondateur de la société Valorex, ont signé une convention-cadre qui vise à organiser leurs collaborations dans les domaines de la nutrition humaine, de la santé animale et de l’environnement.

19 December 2019